Kardex (KARN) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
12 Mar, 2026Executive summary
Achieved all-time high bookings (€981.6m), net revenues (€850.4m), and EBIT (€101.2m) in 2025 despite geopolitical and trade uncertainties.
Accelerated growth strategy launched, targeting €1.5 billion net revenue by 2029–2031, with major investments in sales, marketing, innovation, and digitalization.
Acquired majority shares of ROCKETSOLUTION, adding a fourth business unit and enhancing the solution portfolio.
Gained significant market share in both automated products and standardized systems in a flat market.
Dividend proposed at CHF 6 per share, unchanged from 2024.
Financial highlights
Bookings increased by 24.1% year-over-year, nearing CHF 1 billion for the first time.
Net revenues grew 7.5% year-over-year to €850.4m, with a strong backlog for 2026.
EBIT reached €101.2 million, surpassing €100 million for the first time; EBIT margin at 11.9%.
Gross profit margin declined to 34.1% due to sales mix and higher personnel expenses.
Free cash flow dropped to €20.5 million, mainly due to higher CapEx and increased net working capital.
Result for the period dropped 48.3% to €41.8m, mainly due to non-cash write-off related to Rocket acquisition.
Outlook and guidance
Net revenue growth for 2026 expected to be above 14%, with financial targets confirmed.
EBIT margin guidance for 2026 remains slightly below 12%.
Continued elevated CapEx of CHF 40–50 million expected for 2026 and 2027, with possible reduction if Asian factory plans are scaled back.
Positive net working capital momentum anticipated in 2026, with higher cash inflows from project execution.
U.S. market expected to rebound in 2026, especially with government and industry spending.
Medium-term growth guidance maintained, with order intake momentum expected in the teens for 2026.
Group targets: €1.5bn net revenues by 2029-2031, EBIT margin 10-14%, ROIC >25%.
Latest events from Kardex
- Kardex targets EUR 1.5bn revenue by 2029–2031, driven by healthcare automation and innovation.KARN
Investor Day 20254 Nov 2025 - Bookings and revenues rose sharply, with strong segment growth and a positive outlook.KARN
H1 202531 Jul 2025 - Double-digit growth, high cash flow, and automation trends drive a strong outlook.KARN
H1 202413 Jun 2025 - Record 2024 results, higher dividend, and raised growth targets amid robust intralogistics demand.KARN
H2 20246 Jun 2025